Recent Updates
Recently added Catalysts

CRB-701

Phase 2

Solid Tumor, Adult | Small molecule | Oncology |Corbus Pharmaceuticals Holdings, Inc.|Last Updated: Jan 7, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment348
FDA Designations
FAST_TRACK
Clinical trial landscape

CRB-701 · 1 trial · 1 indication

Phase 1/2 1
NCT06265727A Phase 1/2 Study to Investigate CRB-701 in Solid TumorsSolid Tumor, Adult
RECRUITING348 Analytics
PHASE1/PHASE2RECRUITING
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Solid Tumor, Adult
NCT06265727348
Unlock trial analytics
Study Design & Arms
Interventions
NameTypeDescription
CRB-701DRUGNectin-4 targeted Antibody Drug Conjugate (ADC)
Anti-PD-1DRUGcheckpoint inhibitor
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06265727studyFirstPostDate: changed